Source-grounded facts extracted from MACROGENICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Karen Ferrante resigned as director at MACROGENICS INC.
“On July 1, 2026, Karen Ferrante, M.D. provided notice to the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”) of her decision to resign from the Board, effective September 1, 2026.”
MACROGENICS INC shareholders approved To approve an amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan (the "2023 Plan") to increase the number of shares of our common stock available for issuance thereunder by 1,250,000 shares. at the 2026-05-19 meeting.
“Proposal 4 . To approve an amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan (the "2023 Plan") to increase the number of shares of our common stock available for issuance thereunder by 1,250,000 shares. Stockholders approved the amendment to the 2023 Plan. The voting results were as follows: For Against Abstain Broker Non-Votes 25,600,112 1,671,102 75,091 9,397,708”
MACROGENICS INC shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement. at the 2026-05-19 meeting.
“Proposal 3 . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement. Stockholders approved the compensation of the Company's named executive officers. The voting results were as follows: For Against Abstain Broker Non-Votes 26,624,952 526,125 195,228 9,397,708”
MACROGENICS INC shareholders approved The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2026. at the 2026-05-19 meeting.
“Proposal 2 . The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2026. Proposal 2 was approved. The voting results were as follows: For Against Abstain Broker Non-Votes 36,689,683 40,552 13,778 —”
MACROGENICS INC shareholders approved Election of four nominees to serve as Class I directors, each for a term of three years. at the 2026-05-19 meeting.
“Proposal 1 . The election of four nominees to serve as Class I directors, each for a term of three years. All director nominees were elected. The voting results were as follows: Nominees For Withheld Broker Non-Votes Scott Koenig, M.D., Ph.D. 26,353,906 992,399 9,397,708 Federica O'Brien 26,467,370 878,935 9,397,708 Eric Risser 27,174,501 171,804 9,397,708”
MACROGENICS INC reported financial results for the quarter ended March 31, 2026.
“On May 13, 2026, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2026.”
MACROGENICS INC entered into Asset Purchase Agreement with Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC valued at $122.5 million in cash (effective 2026-05-11).
“On May 11, 2026, MacroGenics, Inc., a Delaware corporation (the "Company"), entered into an Asset Purchase Agreement (the "Purchase Agreement") with Bora Pharmaceuticals Co., Ltd., a company organized under the laws of Taiwan ("Bora"), and Bora Biologics USA, LLC, a Delaware limited liability company (collectively, the "Purchaser"), pursuant to which the Company agreed to sell to the Purchaser assets and current liabilities related to its GMP manufacturing operations, including its CDMO business (the "CDMO Operations") currently conducted by the Company at its manufacturing facility located at 9704 Medical Center Drive, Rockville, Maryland and related warehouse operations located at 4735 Arcadia Drive, Frederick, Maryland (excluding all research and related assets and operations of the Company) (the "Transaction").”
MACROGENICS INC amended First Amendment to the Purchase and Sale Agreement with Sagard Healthcare Partners valued at $60.0 million additional cash payment, aggregate purchase price $130.0 million (effective 2026-05-01).
“On May 1, 2026, MacroGenics, Inc. (the “Company”) and an entity affiliated with Sagard Healthcare Partners (“Sagard”) entered into a First Amendment (the “First Amendment”) to the Purchase and Sale Agreement, dated as of June 9, 2025 (the “Royalty Purchase Agreement”), pursuant to which the Company previously sold to Sagard its right to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) under the Company’s Global Collaboration and License Agreement dated as of October 24, 2017, as amended (the “License Agreement”), with Incyte Corporation.”
MACROGENICS INC reported the year ended December 31, 2025 results: revenue $149.5 million.
“cash equivalents and marketable securities balance as of December 31, 2025, was $189.9 million, compared to $201.7 million as of December 31, 2024. • Revenue : Total revenue was $149.5 million for the year ended December 31, 2025, compared to $150.0 million for the year ended December 31, 2024. Total revenue included contract manufacturing revenue of $52.6 million for”
Beth Smith was appointed as Vice President, Controller, Treasurer and Principal Accounting Officer at MACROGENICS INC.
“On November 19, 2024, the Board appointed Beth Smith as the Company’s Vice President, Controller, Treasurer and Principal Accounting Officer, effective as of the Effective Date.”
Lynn Cilinski resigned as Vice President, Controller, Treasurer and Principal Accounting Officer at MACROGENICS INC.
“On November 18, 2024, Ms. Lynn Cilinski notified MacroGenics, Inc. (the “ Company ”) of her intention to retire from her position as Vice President, Controller, Treasurer and Principal Accounting Officer, effective January 2, 2025”
Scott Koenig resigned as President and Chief Executive Officer at MACROGENICS INC.
“On October 25, 2024, Dr. Scott Koenig, the President and Chief Executive Officer of MacroGenics, Inc. (the “ Company ”) and the Company entered into a separation and consulting agreement, dated October 25, 2024 (the “ Separation Agreement ”), which provides for the terms of Dr. Koenig’s separation from employment, effective February 28, 2025”
MACROGENICS INC reported financial results for quarter ended March 31, 2024.
“On May 9, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2024.”
MACROGENICS INC reported financial results for the year ended December 31, 2023.
“On March 7, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2023.”
MACROGENICS INC reported the quarter ended September 30, 2023 results: revenue $10.4 million.
“Total revenue was $10.4 million for the quarter ended September 30, 2023, compared to total revenue of $41.7 million for the quarter ended September 30, 2022.”
MACROGENICS INC amended Asset Purchase Agreement with Provention Bio, Inc. valued at Amendment to incorporate Sales Milestone Payment obligation and guaranty by Sanofi, and eliminate Pr (effective 2023-09-19).
“On September 19, 2023, the Company and Provention Bio entered into an amendment of the Asset Purchase Agreement (the “Asset Purchase Agreement Amendment”) to incorporate the Sales Milestone Payment obligation from the Royalty Purchase Agreement, along with a guaranty of such obligation by Sanofi and to eliminate any obligation for Provention Bio to pay the Royalty Interest to the Company.”
MACROGENICS INC terminated Royalty Purchase Agreement with DRI Healthcare Acquisitions LP valued at Mutual Termination Agreement terminated the Royalty Purchase Agreement (effective 2023-09-19).
“On September 19, 2023, the Company and Aventis concurrently entered into a Mutual Termination Agreement terminating the Royalty Purchase Agreement.”
MACROGENICS INC reported the quarter ended June 30, 2023 results: revenue $13.1 million.
“Total revenue was $13.1 million for the quarter ended June 30, 2023, compared to total revenue of $26.0 million for the quarter ended June 30, 2022.”
MACROGENICS INC shareholders approved Approval of the MacroGenics, Inc. 2023 Equity Incentive Plan. at the 2023-05-31 meeting.
“Proposal 4 . To approve the MacroGenics, Inc. 2023 Equity Incentive Plan (the "2023 Plan"). Stockholders approved the 2023 Plan. The voting results were as follows: For Against Abstain Broker Non-Votes 32,287,594 16,781,647 5,964 3,614,159”
MACROGENICS INC shareholders approved Advisory vote to approve the compensation of the Company's named executive officers. at the 2023-05-31 meeting.
“Proposal 3 . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement. Stockholders approved the compensation of the Company's named executive officers. The voting results were as follows: For Against Abstain Broker Non-Votes 43,633,412 5,433,960 7,833 3,614,159”
MACROGENICS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023. at the 2023-05-31 meeting.
“Proposal 2 . The ratification of the appointment by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2023. Proposal 2 was approved. The voting results were as follows: For Against Abstain Broker Non-Votes 47,636,172 5,024,405 28,787 —”
MACROGENICS INC shareholders approved Election of three nominees to serve as Class I directors, each for a term of three years. at the 2023-05-31 meeting.
“Proposal 1 . The election of three nominees to serve as Class I directors, each for a term of three years. All director nominees were elected. The voting results were as follows: Nominees For Withheld Broker Non-Votes Scott Koenig, M.D., Ph.D. 43,810,609 5,264,596 3,614,159 Federica O'Brien 43,467,303 5,607,902 3,614,159 Jay Siegel, M.D. 41,788,095 7,287,110 3,614,159”
MACROGENICS INC reported financial results for the year ended December 31, 2022.
“On March 15, 2023, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2022.”
MACROGENICS INC entered into Purchase and Sale Agreement with DRI Healthcare Acquisitions LP valued at $100 million (effective 2023-03-08).
“On March 8, 2023 (the “Execution Date”), MacroGenics, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Royalty Purchase Agreement”) with DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, for the sale to DRI of the Company’s single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) (the “DRI Transaction”)”
Meenu Chhabra Karson was appointed as Director at MACROGENICS INC.
“On January 3, 2023, the Board of Directors (the "Board") of MacroGenics, Inc. (the "Company") approved the appointment of Meenu Chhabra Karson to serve as a director on the Board, effective January 3, 2023 (the “Effective Date”).”
Margaret Liu was appointed as Director at MACROGENICS INC.
“On December 19, 2022, the Board of Directors (the "Board") of MacroGenics, Inc. (the "Company") approved the appointment of Margaret Liu, M.D. to serve as a director on the Board, effective January 3, 2023”
MACROGENICS INC amended Fifth Amendment with ARE-Maryland No. 45, LLC (effective 2022-12-14).
“On December 14 , 2022 (the “Execution Date”) MacroGenics, Inc. (the “Company”) entered into a Fifth Amendment (the “Amendment”) to its existing lease agreement (the “Lease”) with ARE-Maryland No. 45, LLC (the “Landlord”), for 122,600 square feet located at 9704 Medical Center Drive in Rockville, Maryland (the “Premises”).”
MACROGENICS INC reported the quarter ended September 30, 2022 results: revenue $41.7 million.
“Total revenue, consisting primarily of revenue from collaborative agreements, was $41.7 million for the quarter ended September 30, 2022, compared to total revenue of $15.7 million for the quarter ended September 30, 2021.”
Paulo Costa departed as Chair of the Board at MACROGENICS INC.
“replacing Mr. Paulo Costa, who served in such position until his term as a director expired on May 19, 2022”
Paulo Costa departed as Director at MACROGENICS INC.
“who served in such position until his term as a director expired on May 19, 2022 upon the conclusion of the 2022 Annual Meeting of Stockholders”
William K. Heiden was appointed as non-executive Chair of the Board at MACROGENICS INC.
“Mr. Heiden has been appointed to serve as non-executive Chair of the Board, effective immediately, replacing Mr. Paulo Costa”
William K. Heiden was appointed as Director at MACROGENICS INC.
“approved the appointment of William K. Heiden to serve as a director on the Board, effective immediately.”
Kenneth Galbraith resigned as Director and Audit Committee Chair at MACROGENICS INC.
“On January 5, 2022 , Mr. Kenneth Galbraith, a member of the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”), notified the Board of his decision to resign from the Board, effective immediately.”
Paulo Costa departed as Chair of the Board at MACROGENICS INC.
“On September 23, 2021, Mr. Paulo Costa, a member of the board of directors (the “Board”) of MacroGenics, Inc. (the “Company”), notified the Board that he will not stand for reelection as a director of the Company upon expiration of his current term.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.